H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Gain Therapeutics today and set a price target of $8.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ram Selvaraju has given his Buy rating due to a combination of factors related to Gain Therapeutics’ lead asset and expanding pipeline. He emphasizes that GT-02287 has shown encouraging Phase 1b results in Parkinson’s disease, including sustained safety and tolerability, strong biomarker shifts indicating target engagement, and signals of potential disease stabilization over several months of dosing.
He also highlights that Gain is broadening its platform with a new GCase modulator series led by GT-04686, discovered via its Magellan platform, which has demonstrated activity in preclinical models and may offer superior brain penetration and dosing flexibility. The presence of a second, chemically distinct candidate targeting a different allosteric site provides diversification and risk mitigation, supporting his conviction in the company’s long-term value and underpinning his reiterated Buy rating and $8 twelve-month price target.
In another report released on March 26, Maxim Group also maintained a Buy rating on the stock with a $7.00 price target.